Clinical trial registry record

A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD）

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Unknown.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated October 1, 2020.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT04572698
Last registry update
October 1, 2020
Status
Unknown
Phase
Phase 3
Sponsor
Luye Pharma Group Ltd.
Enrollment
416
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
RANDOMIZED · PARALLEL · TREATMENT · DOUBLE
Evidence population
Human clinical study registration
Participants
416
Population
ALL · 50 Years
Duration
2020-11-01 to 2023-12-01
Intervention
LY09004; Eylea
Comparator
EYLEA
Outcomes measured
BCVA（best corrected visual acuity ） — week 24; BCVA — week 4, week 8, week 12, week 16, week 20, week 28, week 32, week 36, week 40, week 44, week 48, week 52; Letter — week 24, week 52; Central television omentum thickness — week 24, week 52; CNV(Choroidal neovascularization) leakage area — week 24, week 52
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Title supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON